国产比阿培南治疗中度至重度呼吸道感染疗效观察

Effect of biapenem in the treatment of moderate to severe respiratory tract infection

目的评价国产比阿培南治疗中度至重度呼吸道感染的疗效和安全性。方法118例中度至重度呼吸道感染患者随机分为2组,组1(59例)静脉滴注比阿培南(国产);组2(59例)静脉滴注亚胺培南-西司他丁钠,疗程均为7～14d。结果两组临床有效率和细菌清除率分别为74.57%对61.02%,90.63%对88.24%;不良反应发生率分别为5.08%和8.47%,组间差异均未见统计学显著性(P>0.05)。结论国产比阿培南治疗中度至重度呼吸道感染的疗效和安全性与亚胺培南-西司他丁钠相当,安全有效。

Objective To evaluate the clinical efficacy and safety of biapenem in the treatment of moderate to severe respiratory tract infection. Methods 118 patients with moderate to severe respiratory tract infection were randomly divided into two groups. Biapenem （n=59） or imipenem-cilastatin （n=59） were administered by intravenous infusion for 7-14 days. Results The clinical effective rate and bacteria elimination rate of two groups were 74.57% vs 61.02% and 90.63% vs 88.24% respectively. The rate of adverse reactions were 5.08% and 8.47% respectively. There was no significant difference between two groups （P〉0.05）. Conclusion Biapenem seems treatment of moderate to severe respiratory tract infection. to be as effective and safe as imipenem-cilastatin for the